BioVie Inc. announced positive topline results Wednesday from a Phase II biomarker study in Alzheimer's disease (AD) showing patient improvements in cognition and reductions in neural inflammation following treatment with NE3107.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,